DeutschNewstral
Article
jdsupra.com on 2016-11-02 19:29
Celltrion’s Herceptin Biosimilar Submitted For Approval in Europe
Related news
- Amgen Has Filed for EU Approval for Herceptin® (Trastuzumab) Biosimilarjdsupra.com
- EMA Accepts Mylan and Biocon’s MAA for a Herceptin (Trastuzumab) Biosimilarjdsupra.com
- Update on Celltrion’s Infliximab Biosimilarjdsupra.com
- Celltrion Seeks EMA Approval for Avastin Biosimilarjdsupra.com
- EMA Committee Recommends Approval for Celltrion’s Truxima (rituximab) Biosimilarjdsupra.com
- Biosimilar Approval Updates in Europe and Chinajdsupra.com
- Samsung Bioepis Seeks Regulatory Approval for an Adalimumab Biosimilar in Europe and South Koreajdsupra.com
- FDA Approves Celltrion’s Trastuzumab Biosimilarjdsupra.com
- 2017 Biosimilar Approvals in Europejdsupra.com
- Takeaways from FDA’s Approval of the First Interchangeable Biosimilar for Humira®jdsupra.com
- FDA approves a fourth biosimilar of HERCEPTINjdsupra.com
- Celltrion's Proposed REMICADE® Biosimilar Recommended for Approvaljdsupra.com
- STADA and Xbrane Announce Approval of Ranibizumab Biosimilar in Europejdsupra.com
- Sandoz Obtains FDA Approval for Adalimumab Biosimilarjdsupra.com
- Celltrion’s Trastuzumab Biosimilar Earns WHO Prequalification Statusjdsupra.com
- Celltrion’s CT-P6 Demonstrates Equivalent Safety, Efficacy With HERCEPTINjdsupra.com
- Enbrel Biosimilar in Europe and USjdsupra.com
- MPfizer says FDA failed to approve Herceptin biosimilarmarketwatch.com
- Teva Receives Approval for First Ophthalmology Biosimilar in Europejdsupra.com
- FDA Approves Ogivri, Mylan’s Biosimilar Version of Herceptinjdsupra.com